Korea to domestically produce three critical cancer, antibiotic drugs
The food and drug safety ministry will commission local manufacturers to make doxorubicin, daunorubicin and daptomycin for supply within the year, as a revised pharmaceutical law takes effect Nov. 12.

South Korea's food and drug safety ministry said Thursday it will commission domestic manufacturers to produce three essential cancer and antibiotic treatments and supply them to hospitals within the year, aiming to close gaps in the supply of drugs used in life-threatening conditions.
The three items are Boryung's freeze-dried doxorubicin injection, used in chemotherapy for liver cancer patients; Korea United Pharm's daunorubicin injection for acute myeloid leukemia; and Kunil Biopharm's daptomycin injection for severe infections including methicillin-resistant bloodstream infections. The ministry said the two drugs it had previously brought in from overseas on an emergency basis, doxorubicin and daptomycin, would now be made at home, while daunorubicin was included pre-emptively because its supply was recently interrupted, threatening timely treatment for children with fast-progressing leukemia.
The ministry runs the commissioned-manufacturing program through the Korea Rare and Essential Medicines Center, which buys and distributes the output. This year's program covers four products in total, including the dacarbazine injection added in the first half — the largest annual figure since the scheme began in 2016. Eight pharmaceutical companies now take part, producing 11 drugs designated as national essential medicines.
The government's role in the program gains a legal footing on Nov. 12, when a revised Pharmaceutical Affairs Act takes effect. It allows the minister of food and drug safety to request that local manufacturers produce essential medicines whose supply cannot be secured stably and to pay the associated costs.
The ministry said it will work with the medical community, the pharmaceutical industry and related agencies to identify essential medicines at risk of shortage early and expand support, including commissioned manufacturing, so that patients receive critical treatments on time.
What this article is based on
Every fact in this article can be checked against the primary documents below.
- Government식품의약품안전처 정부 보도자료· Ministry of Food and Drug Safety· accessed Nov. 12, 2026
- Government공시 원문(정책브리핑 보도자료)· korea.kr· accessed Nov. 12, 2026
© New Era Korea Daily. All rights reserved.